Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
06 févr. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing.
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
05 févr. 2025 16h15 HE
|
Myriad Genetics, Inc.
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
05 févr. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
29 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference.
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
23 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics launches a new educational website providing information about reproductive and prenatal genetic testing called "Know More Sooner."
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
21 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal).
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
15 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance.
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09 janv. 2025 16h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 11h27 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.